Market Place
Sourcing Support
Cancer scientist failed to disclose industry payments — does that matter?
10 Sep 2018 //
ENDPTS
Novartis considers filings for PI3K drug in breast cancer
24 Aug 2018 //
PMLIVE
Novartis succeeds where Roche failed with PI3K breast cancer drug
23 Aug 2018 //
PHARMAPHORUM
Novartis just boasted of a big PhIII PI3K success
23 Aug 2018 //
ENDPTS
Novartis trial win lifts profile of new breast cancer drug
23 Aug 2018 //
REUTERS
Novartis hands off buparlisib to China`s Adlai Noryte
12 Jul 2018 //
FIERCE BIOTECH
Novartis punts a late-stage PI3K drug to China’s biotechs
12 Jul 2018 //
ENDPTS
Two Roche Cancer Drugs Get Disappointing Results
04 Jun 2018 //
BIOSPACE
ASCO: Roche punts taselisib after weak data, severe side effects
04 Jun 2018 //
FIERCE BIOTECH
Roche drugs show limited benefit in lung, breast cancer trials
04 Jun 2018 //
REUTERS
Roche dumps PhIII taselisib after harsh side effects for breast cancer
03 Jun 2018 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.